Progyny logo

Progyny(NASDAQ) PGNY

Market Cap$2.23BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)+78%
5 Year-54%
1 Year+52%
1 Month+11%
Premium Feature
Moneyball Superscore
76/100
$29.12
+2.39%
+0.68Today
After hours$29.11-$0.01 (-0.03%)
Progyny last closing stock price
MetricPriceDate
Last closeUSD 29.122026-10-22
Progyny stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+6.06%USD 27.462026-10-15
1 month+10.98%USD 26.242026-09-22
3 month-6.64%USD 31.192026-07-24
Year to date+13.4%USD 25.682025-12-31
1 year+51.9%USD 19.172025-10-22
3 year-8.25%USD 31.742023-10-23
5 year-53.93%USD 63.212021-10-22
Since inception+78.42%USD 15.942019-10-25

Progyny Financials at a Glance

Market Cap

$2.23BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$1.31B

Net Income (TTM)

$78.63M

EPS (TTM)

$0.92

P/E Ratio

31.63

Dividend

$0.00

Beta (Volatility)

1.02 (Average)

Price

$29.12

Volume

2

Open

$28.59

Previous Close

$29.12

Daily Range

$28.47 - $29.24

52-Week Range

$16.10 - $33.07

Estimated Earnings Date

Nov 5, 2026

PGNY: Motley Fool Moneyball Superscore

76

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Progyny

Progyny NASDAQ:PGNY helps companies provide fertility benefits to their employees. It makes starting a family easier for millions of people. The company connects members with specialized doctors and pharmacy services.

Smart Cycles and Meds

  • Fertility Benefits Solution: Proprietary treatment bundles called Smart Cycles that include diagnostic testing and medical services.
  • Progyny Rx: Integrated pharmacy program providing access to medications and specialist support during treatment.
  • Care Management Services: Direct support from patient advocates and access to a curated network of specialists.
  • Population-Based Services: Digital tools and education for all employees; accounted for 1% of revenue for the six-month period ended June 30, 2026.

Building the Platform

  • Authorized a $200 million share repurchase program in November 2025.
  • Launched an additional $200 million share repurchase program in May 2026.
  • Completed a business acquisition in the first half of 2025 to expand offerings.
  • Expanded the client base to over 600 employers across more than 40 different industries.

Clinical Results and Care

Progyny uses a data-driven platform that delivers clinical results exceeding national averages for live births and single embryo transfers. The company manages a selective network of fertility specialists while providing members with dedicated advocates to guide their treatment journeys.

The Financial Scorecard

  • Total revenue was $679.0 million for the six-month period ended June 30, 2026, up 3% year over year.
  • Gross profit reached $172.4 million in the six-month period ended June 30, 2026, up 11% year over year.
  • Adjusted EBITDA, a non-GAAP measure, was $118.7 million for the six-month period ended June 30, 2026.
  • The company held $152.6 million in cash and cash equivalents as of June 30, 2026.
  • Net income rose to $52.3 million in the six-month period ended June 30, 2026.

Bottom Line

Progyny has transitioned from a niche fertility provider to a diversified women’s health platform serving millions of members. Its expansion into pharmacy and broader health solutions supports its role as a specialized benefits manager for large employers.

AI Generated • Aug 7, 2026

Industry

Healthcare Providers and Services

Employees

856

CEO

Peter Anevski

Headquarters

New York City, NY 10018, US

PGNY Financials

Key Financial Metrics (TTM)

Gross Margin

24.57%

Operating Margin

8.55%

Net Income Margin

6.00%

Return on Equity

15.98%

Return on Capital

15.68%

Return on Assets

10.98%

Earnings Yield

3.16%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.23BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

76.73M

Volume

2

Avg. Volume

1.12M

Financials (TTM)

Gross Profit

$322.09M

Operating Income

$112.13M

EBITDA

$127.06M

Operating Cash Flow

$247.20M

Capital Expenditure

-$29.21M

Free Cash Flow

$217.99M

Cash & ST Invst.

$236.93M

Total Debt

$26.97M

Progyny Performance Analysis

Progyny annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 786,913,00057.2%
20232023-12-31USD 1,088,598,00038.3%
20242024-12-31USD 1,167,221,0007.2%
20252025-12-31USD 1,288,661,00010.4%
Progyny sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-5.9%
Q42025-12-311.6%
Q12026-03-313.2%
Q22026-06-306.7%
Progyny annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 0.30-53.7%
20232023-12-31USD 0.62102.9%
20242024-12-31USD 0.57-7.6%
20252025-12-31USD 0.6514.4%
Progyny sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-21.1%
Q42025-12-31-6.7%
Q12026-03-31107.1%
Q22026-06-3017.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$350.51M

+5.3%

Gross Profit

$89.30M

+13.1%

Gross Margin

25.48%

N/A

Market Cap

$2.23BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.64M

N/A

Employees

846

N/A

Net Income

$28.05M

+63.9%

EBITDA

$44.24M

+56.4%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$236.93M

-22.3%

Total Debt

$26.97M

+5.7%

Accounts Receivable

$257.48M

-5.3%

Inventory

$0.00

N/A

Long Term Debt

$22.50M

-11.8%

Short Term Debt

$4.48M

N/A

Return on Assets

10.98%

N/A

Return on Invested Capital

23.57%

N/A

Free Cash Flow

$83.81M

+66.8%

Operating Cash Flow

$96.37M

+73.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
OMDAOmada Health
$18.98-3.46%
HQYHealthEquity, Inc.
$100.97+3.16%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$82.11-20.47%
KORUDirexion Shares ETF Trust - Direxion Daily Msci South Korea Bull 3x Shares
$10.19-14.66%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$53.45+20.68%
NOKNokia
$7.88-14.81%

Questions About PGNY

What is the current price of Progyny?

Progyny is trading at $29.12 per share.

What is the 52-week range for Progyny?

Over the past 52 weeks, Progyny has traded between $16.10 and $33.07.

How much debt does Progyny have?

As of the most recent reporting period, Progyny reported total debt of $26.97M.

How much cash does Progyny have on hand?

Progyny reported $152.63M in cash and cash equivalents in its most recent financial results.

What is Progyny’s dividend yield?

Progyny does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.